Spots Global Cancer Trial Database for Study of XL999 in Patients With Previously Treated Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of XL999 in Patients With Previously Treated Ovarian Cancer
Official Title: A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer
Study ID: NCT00277290
Conditions
Interventions
Study Description
Brief Summary: This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
California Cancer Care, Inc., Greenbrae, California, United States
Hematology/Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States
University of Chicago, Chicago, Illinois, United States
Joliet Oncology-Hematology Associates, Ltd, Joliet, Illinois, United States
Indiana University Cancer Center, Indianapolis, Indiana, United States
Harry and Jeanette Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bradley Cohen, New City, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Contact Details
Name: Lynne A. Bui, MD
Affiliation: Exelixis
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
